SLICC/ACR Criteria Don't ID Severe Internal Disease in SCLE

This article originally appeared here.
Share this content:
SLICC/ACR Criteria Don't ID Severe Internal Disease in SCLE
SLICC/ACR Criteria Don't ID Severe Internal Disease in SCLE

WEDNESDAY, April 27, 2016 (HealthDay News) -- Neither the American College of Rheumatology (ACR) nor the Systemic Lupus International Collaborating Clinics (SLICC) criteria distinguishes patients with subacute cutaneous lupus erythematosus (SCLE) with major internal disease from those without, according to research published in the May issue of the Journal of the American Academy of Dermatology.

Janice Tiao, from the Michael J. Crescenz Philadelphia Department of Veterans Affairs Medical Center, and colleagues conducted a retrospective analysis of 107 patients with SCLE to determine how patients with SCLE/SLE meet the ACR and SLICC criteria.

The researchers found that using both sets of criteria, patients with SCLE/SLE were more likely to have oral ulcers, positive anti-double-stranded DNA antibodies, and positive antinuclear antibody test findings than those with only SCLE. Using the SLICC criteria, patients with SCLE/SLE were more likely to have low complement. A statistically insignificant increase was seen in individuals meeting the SLIC criteria.

"Most patients with SCLE who formally meet criteria for SLE do so based on the laboratory and mucocutaneous criteria. Neither the ACR nor SLICC criteria distinguish patients with SCLE and major internal disease from patients with SCLE without major internal disease," the authors conclude. "Clinicians should not rely on these criteria to identify patients with subacute cutaneous lupus erythematosus with significant systemic disease."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »